SureTrader Nadex Advertisement PGUS
Home > Boards > US Listed > Biotechs >

Merrimack Pharmaceuticals, Inc. (MACK)

Add MACK Price Alert      Hide Sticky   Hide Intro
Moderator: $Pistol Pete$
Search This Board: 
Last Post: 3/29/2017 9:52:12 PM - Followers: 62 - Board type: Free - Posts Today: 0

Welcome to Merrimack Pharmaceuticals, Inc. (MACK) Board!!!

At Merrimack, researchers, clinicians, professionals, and, yes, engineers work together in a multidisciplinary, team-based environment. All are committed to a single vision. Building cures for cancer.


       Our Leadership

           Robert J. Mulroy has served as our President and Chief Executive Officer and a member of our board of directors since May 1999. Prior to joining us, Mr. Mulroy worked as a management consultant in the pharmaceutical and healthcare                  industries. Mr. Mulroy has also worked as a consultant in the field of international development and has served as an advisor to multiple start-up companies in the biotechnology industry. Mr. Mulroy holds a master’s degree in public and                    private  management from Yale University and a BA from Stanford University.

           Yasir B. Al-Wakeel, BM BCh, has served as our Chief Financial Officer and Head of Corporate Development since August 2015. Dr. Al-Wakeel previously served in various capacities at Credit Suisse, an investment bank, from January 2008            to June 2015. While at Credit Suisse, Dr. Al-Wakeel was most recently a Director of Healthcare Investment Banking focused on biotechnology and, prior to that role, he was an Equity Research Analyst covering the biotechnology and                        specialty pharmaceuticals sectors. Before joining Credit Suisse, Dr. Al-Wakeel was a practicing physician, holding both clinical and academic medical posts. Dr. Al-Wakeel holds a BM BCh (Doctor of Medicine) from Oxford University, an MA            in theology from Cambridge University and a BA from Cambridge University.

           Peter N. Laivins has served as our Head of Development since May 2014. Mr. Laivins served as our Vice President of Clinical Development from October 2011 to May 2014. Previously, Mr. Laivins ran an independent consulting practice                  specializing in oncology and neuroscience from January 2010 to October 2011. Prior to that, Mr. Laivins served as Vice President of Strategic Marketing at Elan Corporation, plc, a biopharmaceutical company, from 2006 to January 2010.                Mr. Laivins began his career at Pfizer Canada, joined Pfizer International in New York in 1995 and held positions of increasing responsibility at Pfizer Inc., culminating as Group Leader of Pfizer US Oncology Marketing until 2006. Mr. Laivins            holds an  MBA and a BS from McGill University.

           Gavin MacBeath, PhD, is a founder of Merrimack and Head of Translational Medicine. Dr. MacBeath leads translational research and drives our innovative diagnostic programs, helping to ensure we get the right drug to the right patient at                the right time. He is also a founder of Chestnut Pharmaceuticals, serves on the Scientific Advisory Board of Aushon Biosciences and is a Lecturer and Principal Investigator at Harvard Medical School. He joined Merrimack in 2009 after                    serving on the  faculty in the Department of Chemistry and Chemical Biology at Harvard University for eight years where he focused on developing and applying protein microarray technology to facilitate basic research in the area of systems            biology. Dr. MacBeath holds a Bachelors of Science from University of Manitoba, Canada, and a PhD in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute in La Jolla, California.

           William M. McClements has served as our Head of Corporate Operations since September 2011. Previously, Mr. McClements served as Chief Human Resources Officer of Integreon Managed Solutions, Inc., a global research and business            services company, from May 2010 to September 2011. Prior to that, Mr. McClements served as Chief Operating Officer and a partner at Monitor Group, a global strategic advisory firm, where he worked from 1987 to May 2010. From                        September 2009 to March 2010, Mr. McClements also served as Acting President of Be the Change, Inc., a nonprofit focused on creating national issue-based campaigns. Mr. McClements holds an MBA from Harvard Business School and              a BA from Williams College.

           Birgit M. Schoeberl, PhD, has served as our Head of Discovery since January 2015. Dr. Schoeberl served as our Senior Vice President of Research from January 2014 to January 2015, as our Vice President of Research from October 2009            to January 2014 and in various other research roles since she joined us in 2003. Prior to joining us, Dr. Schoeberl was a post-doctoral fellow at the Massachusetts Institute of Technology, where she built some of the earliest computational                models of  signaling networks. Dr. Schoeberl holds a PhD in systems biology from the Max Planck Institute for Dynamics of Complex Technical Systems in Germany and an MS in chemical engineering from the University of Karlsruhe in                  Germany.

           Edward J. Stewart has served as our Head of Commercial since December 2011. Mr. Stewart served as our Senior Vice President of Business Development from March 2009 to December 2011 and in various other business development                roles since he joined us in 2001. Mr. Stewart began his career at KPMG Peat Marwick LLP in the life sciences strategy consulting group. Mr. Stewart holds an MBA from the Johnson Graduate School of Management at Cornell University                and a BS from  Bates College.

          William A. Sullivan has served as our Head of Finance and Accounting since August 2015 and our Treasurer since February 2010. Mr. Sullivan served as our Chief Financial Officer from May 2011 to August 2015, as our Vice President of               Finance from February 2010 to May 2011, and as our Controller from November 2007 to February 2010. Previously, Mr. Sullivan served as Corporate Controller of Vette Corp., a thermal management solutions company, from 2004 to 2007.             Mr. Sullivan began his career at Arthur Andersen LLP, where he obtained his certified public accountant license. Mr. Sullivan holds an MBA and an MS in accounting from Northeastern University’s Graduate School of Professional                             Accounting and a BA from Williams College.

     Contact Us

        One Kendall Square
        Building 700, Suite B7201
        Cambridge, MA 02139
        Phone: 617-441-1000



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MACK News: Merrimack to Present at the 2017 American Association for Cancer Research Annual Meeting 03/27/2017 07:00:00 AM
MACK News: Additional Proxy Soliciting Materials (definitive) (defa14a) 03/24/2017 04:07:36 PM
MACK News: Merrimack Initiates Phase 1 Study of MM-310 in Solid Tumors 03/23/2017 07:00:00 AM
MACK News: Confidential Treatment Order (ct Order) 03/22/2017 04:24:04 PM
MACK News: Confidential Treatment Order (ct Order) 03/22/2017 04:12:50 PM
#436  Sticky Note $MACK ~ Merrimack Pharmaceuticals, Inc. due diligence re $Pistol Pete$ 10/26/15 05:04:22 PM
#585   Tomorrow is showtime. Stock has been oddly Rock_nj 03/29/17 09:52:12 PM
#584   $MACK Chart $Pistol Pete$ 03/27/17 06:14:54 PM
#583   Yes, I liked the news also. We'll Rock_nj 03/26/17 06:37:19 AM
#582   Great filing today. They escrowed 60 million for esad1 03/24/17 07:07:54 PM
#581   $MACK - Some interesting tidbits from the recent Rock_nj 03/23/17 10:41:54 PM
#580   Merrimack Initiates Phase 1 Study of MM-310 in Rock_nj 03/23/17 09:24:05 AM
#579   Not usually..most likely scientific origin. Anything legal or esad1 03/23/17 09:21:06 AM
#578   $MACK just got a Confidential Treatment Order from Rock_nj 03/22/17 07:38:56 PM
#577   i doubt that...taxes on what? They are esad1 03/19/17 07:24:49 PM
#576   Other $55 million is for taxes and transaction fees. Rock_nj 03/19/17 05:31:22 PM
#575   This is interesting...they say we sold the company..we esad1 03/19/17 05:00:21 PM
#574   Wells Fargo filed suit this past week. Rock_nj 03/19/17 06:35:28 AM
#573   7.5 MM shares of the short interest is esad1 03/16/17 09:12:05 AM
#572   Merrimack Pharmaceuticals Inc (NASDAQ:MACK) was the recipient of Rock_nj 03/15/17 10:39:01 PM
#571   Mack is ready to run into conference and dividend. Rock_nj 03/15/17 07:17:38 PM
#570   Pro biotech FDA chief coming soon. $MACK Rock_nj 03/13/17 05:43:32 PM
#569   $MACK has strong support going back years at Rock_nj 03/08/17 10:55:35 PM
#568   $MACK Daily & Weekly Charts http://stockcharts $Pistol Pete$ 03/06/17 05:33:11 PM
#567   A bit of a POP today boys and Protocola 03/06/17 04:17:21 PM
#566   We have to approve the proxy. We need esad1 02/08/17 07:33:25 PM
#565   Will MACK finally break out of this sideways CashFreeze 02/06/17 06:54:06 PM
#564   I have glanced at L2 over the past TonyJoe1957 02/03/17 12:52:20 PM
#563   The Trump CEO meet with drug execs yesterday esad1 02/01/17 07:55:47 AM
#562   I see MACK as at least a double tombrady12nh 01/28/17 11:33:20 AM
#561   Do yourself a favor and read the proxy esad1 01/28/17 07:52:52 AM
#560   I stand corrected....Blackrock only increased marginally as their esad1 01/26/17 06:24:29 PM
#559   THey are pretty smart guys... esad1 01/26/17 05:06:57 PM
#558 esad1 01/26/17 05:05:57 PM
#557   You have a link for that? CashFreeze 01/26/17 01:50:53 PM
#556   Wow that's interesting tombrady12nh 01/26/17 12:12:46 PM
#555   Amended 13G filed by went from 3.4MM esad1 01/26/17 10:49:58 AM
#554   The shareholders have to vote for the deal. esad1 01/25/17 09:30:37 PM
#553   When is the dividend? Pennies_Envy 01/25/17 08:28:49 AM
#552   No...I do not think so...The black eye from esad1 01/23/17 08:15:17 PM
#551   Looks like an institution unloaded its position today. TonyJoe1957 01/23/17 11:59:30 AM
#550   Wow this MACK is a non bouncing POS CashFreeze 01/23/17 11:11:29 AM
#549   Yet another RED day & silence is very Protocola 01/20/17 03:32:03 PM
#548   Intraday parabolic on a 2 day chart. TonyJoe1957 01/19/17 10:18:06 AM
#547   I am nibbling some $5 strike June calls. TonyJoe1957 01/19/17 09:45:10 AM
#546   CEO Crocker is just a director....BOD gets no esad1 01/19/17 08:10:26 AM
#545   $MACK Weekly Chart $Pistol Pete$ 01/18/17 09:47:33 PM
#544   New CEO announced. IMO, all the more reason LR77 01/18/17 07:42:23 AM
#543   IMO......MACK BOD & CEO will not (did not) LR77 01/18/17 07:03:49 AM
#542   Bought MACK today on the close....The whole biotech esad1 01/17/17 05:44:33 PM
#541   The Shire standstill is meaningless as both parties esad1 01/17/17 01:07:40 PM
#540   I find your logic flawless. Thanks, again. TonyJoe1957 01/17/17 11:52:12 AM
#539   From what I have heard, I was understanding LR77 01/17/17 11:47:35 AM
#538   It is mostly hypothesis on my part but esad1 01/17/17 11:17:10 AM
#537   I enjoy reading your posts. Thank you! TonyJoe1957 01/17/17 10:46:29 AM
#536   No...The CEO of Ipsen came from Baxalta and esad1 01/17/17 09:46:08 AM